The fifth case is a key milestone in the study because a data safety monitoring board will be able to review the SynerFuse concept, according to a July 26 news release.
“We’re one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic lower back pain,” SynerFuse CEO Justin Zenanko said in the release.
The combination procedure adds a neurostimulator to stimulate the dorsal root ganglion to provide relief to patients with back pain. The study will enroll up to 20 patients, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
